A Look At The Economic Impact Of Drug Patent Differentiation
Recently, the Federal Trade Commission has pushed to compel the delisting of certain patents held by branded drug manufacturers from the U.S. Food and Drug Administration's "Orange Book" database, on the...To view the full article, register now.
Already a subscriber? Click here to view full article